Therapeutic Strategies in the Treatment of Hodgkin Lymphoma
This activity consists of recorded presentations from the "Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team" held in Scottsdale, AZ on April 16-17, 2018.
Treatment of Hodgkin lymphoma is tailored to disease type, disease stage and an assessment of the risk of resistant disease. The current treatment of Hodgkin lymphoma seeks to maximize the risk-benefit ratio of treatment. This activity will discuss therapeutic strategies in the treatment of Hodgkin lymphoma with a focus on tailoring therapy to each patient according to age and his/her risk of short- and long-term toxicity and/or relapse.
At the end of this educational activity, participants should be able to:
- Discuss therapeutic strategies in the treatment of Hodgkin lymphoma.
- Analyze the prognostic factors that can identify patients at risk.
Matthew Lunning, DO
Assistant Professor, Internal Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Sarah Chart, RN
Rebecca Gleason, RN, CCM
Dixon B. Kaufman, MD, PhD, FACS
Tina Rydland, PharmD
V. Silverstein, MD
Disclosures of relevant financial relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content. OHE ensures that the content is independent of commercial bias.
Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.
Dr. Lunning reports: Amgen, Bristol-Myers Squibb Co., Celgene, Constellation Pharmaceuticals, Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals
Juno Therapeutics, Pharmacyclics, TG Therapeutics ((Grant/research support))
AbbVie, ADC therapeutics, Astra-Zeneca, Acerta, Bayer, Celgene Corporation, Epizyme, Genentech, Gilead Sciences, Inc., Janssen, Pharmacyclics, Juno Therapeutics, Kite, Portola, Sanofi-Genzyme, Seattle Genetics, TG Therapeutics (Consultant)
The remaining activity faculty or planners have no financial relationships to disclose.
Method of participation
There are no fees for participating in or receiving credit for this activity.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Participants will receive a certificate upon successful completion of the activity, which includes the following:
- Completing the entire activity
- Completing the pre- and post-activity assessments, activity evaluation and application for certificate of credit
You must be logged into your account to participate in this activity. Get started by clicking "Begin" and viewing the "CE Info"; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. The Area of Practice you indicated in your profile corresponds with your certificate type. A complete listing of all of your activities can be found under "My Account," "My Activities."
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation Statements
The participant will be awarded up to 1.25 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.25 contact hour(s) ([0.125] CEU) in states that recognize ACPE.
Attending the full program will earn 1.25 contact hour(s).
Unique Activity Number(s): JA0007123-0000-18-125-H01-P/T
OptumHealth Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.25 clock hour(s) for Certified Case Managers (CCM).
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
This activity is provided by OptumHealth Education.
There was no commercial support received for this activity.
To view this activity, you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals (HCPs) who have an interest in the treatment of Hodgkin lymphoma.
- 1.25 ACPE - Pharmacist
- 1.25 ACPE - Pharmacy Technician
- 1.25 ANCC
- 1.25 Attendance
- 1.25 CCMC - General